fidaxomicin (Dificid)
Jump to navigation
Jump to search
Indications
- recurrent Clostridium difficile colitis after prior treatment with vancomycin[3] (FDA approved for adults & children >= 6 months)
- may be used 1st line for treatment of Clostridium difficile colitis[4]
Contraindications
Dosage
Tablets: 200 mg
Oral Suspension
Pharmacokinetics
- fidaxomicin is a substrate of P-glycoprotein
Adverse effects
- nausea (11%)/vomiting
- headache
- abdominal pain (6%)
- diarrhea
Drug interactions
- inhibitors of P-glycoprotein (cyclosporine) may increase plasma levels of fidaxomicin
- drug interaction(s) anticonvulsants with anti-bacterial agents
- drug interaction(s) of digoxin in combination with macrolides
- drug interaction(s) of statins with macrolide
- drug interaction(s) of antibiotics with warfarin
- drug interaction(s) of theophylline with macrolide
- drug interaction(s) of macrolides with sulfonylureas
Mechanism of action
- inhibits RNA synthesis by inhibiting RNA polymerases
More general terms
References
- ↑ FDA NEWS RELEASE: May 27, 2011 FDA approves treatment for Clostridium difficile infection http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm257024.htm
- ↑ Prescriber's Letter 18(7): 2011 New Drug: Fidaxomicin (Dificid) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=270710&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 3.0 3.1 Geriatric Review Syllabus, 10th edition (GRS10) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2019
- ↑ 4.0 4.1 NEJM Knowledge+ Gastroenterology
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION DIFICID (fidaxomicin) tablet, oral suspension https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213138lbl.pdf